Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 17/20 | 0.57 |
| ▸ | PIM2 | Q9P1W9 | 16/20 | 0.57 |
| ▸ | PIM3 | Q86V86 | 15/20 | 0.57 |
| ▸ | SCD | O00767 | 2/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798601 | 1.00 | PIM1 (0.57) | PIM1PIM2PIM3SCDSCD5 | |
| SCHEMBL15052557 | 0.94 | PIM2 (0.56) | PIM1PIM2PIM3 | |
| SCHEMBL15052556 | 0.94 | PIM2 (0.56) | PIM1PIM2PIM3 | |
| SCHEMBL797560 | 0.93 | PIM2 (0.65) | PIM1PIM2PIM3 | |
| SCHEMBL797559 | 0.93 | PIM2 (0.65) | PIM1PIM2PIM3 | |
| SCHEMBL798168 | 0.92 | PIM2 (0.55) | PIM1PIM2PIM3 | |
| SCHEMBL798167 | 0.92 | PIM2 (0.55) | PIM1PIM2PIM3 | |
| SCHEMBL12486060 | 0.91 | PIM1 (0.52) | PIM1PIM2PIM3 | |
| SCHEMBL791242 | 0.91 | PIM1 (0.52) | PIM1PIM2PIM3 | |
| SCHEMBL15051938 | 0.90 | PIM2 (0.64) | PIM1PIM2PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616451-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-07-24 | — | — | EP | claimed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | claimed |
| WO-2012036974-A1 | NOVEL THIAZOL-CARBOXIMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | claimed |
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | TSUI HON-CHUNG (CN) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165450-A1 | Novel Thiazol-Carboximide Derivatives as PDK1 Inhibitors | PDK1, PDPK1, PDK2 | PIM1 36/4885PIM2 41/4885PIM3 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.